UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

MARCH 14, 2006

Date of Report (date of Earliest Event Reported)

 

ISOLAGEN, INC.

(Exact Name of Registrant as Specified in its Charter)

 

DELAWARE

 

001-31564

 

87-0458888

(State or Other Jurisdiction of
Incorporation or Organization)

 

(Commission File No.)

 

(I.R.S. Employer Identification No.)

 

405 EAGLEVIEW BLVD., EXTON, PA  19341

(Address of principal executive offices and zip code)

 

(484) 713-6000

 (Registrant’s telephone number, including area code)

 

NOT APPLICABLE

(Former name or former address, if changed from last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).

 

 


 

Item 2.02               Results Of Operations And Financial Condition.

 

On March 14, 2006, Isolagen, Inc. (“Company”) publicly announced financial results for the fiscal year ended December 31, 2005. For further information, please refer to the press release attached hereto as Exhibit 99 which is incorporated by reference herein.

 

Item 9.01                     Financial Statement and Exhibits.

 

(a)           Not applicable.

 

(b)           Not applicable.

 

(c)           Exhibits.

 

99            Press release dated March 14, 2006

 

[THE SIGNATURE PAGE FOLLOWS.]

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ISOLAGEN, INC.

 

 

 

 

 

 

 

 

Date:

March 16, 2006

By:

/s/ Susan S. Ciallella

 

 

 

 

Susan S. Ciallella, CEO